Informator o strukturze Uczelni

Rozwiń
Start > Organizacja uczelni  > Podstawowe jednostki strukturalne  > Wydział Farmaceutyczny  > Katedra Biofarmacji i Farmakodynamiki  > Zakład Biofarmacji i Farmakokinetyki

Zakład Biofarmacji i Farmakokinetyki

Katedra Biofarmacji i Farmakodynamiki

AKTYWNOŚCI PUBLIKACYJNE


Rok:
2021|
2020|2019|2018|2017|2016|2015|2014|2013|2012|2011|2010|2009|2008|2007|2006|2005|2004|2003|2002|2001|2000|1999|1998|1997|1996-1995|1994-1993|1992-1991|1990-1986|1985-1981|1980-1976|1975-1970|

2020:
  • Onichimowski, D., Będźkowska, A., Ziółkowski, H., Jaroszewski, J., Borys, M., Czuczwar M. & Wiczling P. Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial. Pharmacol. Rep 72, 719–729 (2020)
  • Cuevas-Delgado, P., Dudzik, D., Miguel, V. et al. Data-dependent normalization strategies for untargeted metabolomics—a case study. Anal Bioanal Chem 412, 6391–6405 (2020)
  • González-Riano C, Dudzik D, Garcia A, Gil-de-la-Fuente A, Gradillas A, Godzien J, López-Gonzálvez Á, Rey-Stolle F, Rojo D, Ruperez FJ, Saiz J, Barbas C. Recent Developments along the Analytical Process for Metabolomics Workflows. Anal Chem. 2020 Jan 7;92(1):203-226.
  • Polonis, K., Wawrzyniak, R., Daghir-Wojtkowiak, E., Szyndler, A., Chrostowska, M., Melander, O., Hoffmann, M., Kordalewska, M., Raczak-Gutknecht, J., Bartosińska, E., Kaliszan, R., Narkiewicz, K., & Markuszewski, M. J. (2020). Metabolomic Signature of Early Vascular Aging (EVA) in Hypertension. Frontiers in molecular biosciences, 7, 12.
  • Rajska A, Buszewska-Forajta M, Rachoń D, Markuszewski MJ. Metabolomic Insight into Polycystic Ovary Syndrome—An Overview. International Journal of Molecular Sciences. 2020; 21(14):4853
  • Struck-Lewicka W, Wawrzyniak R, Artymowicz M, Kordalewska M, Markuszewski M, Matuszewski M, Gutknecht P, Siebert J, Markuszewski MJ. GC-MS-based untargeted metabolomics of plasma and urine to evaluate metabolic changes in prostate cancer. J Breath Res. 2020 Sep 24;14(4):047103
  • Lewkowicz A, Bogdanowicz R, Bojarski P, Pierpaoli M, Gryczyński I, Synak A, Mońka M, Karczewski J, Struck-Lewicka W, Wawrzyniak R, Markuszewski MJ. The Luminescence of 1,8-Diazafluoren-9-One/Titanium Dioxide Composite Thin Films for Optical Application. Materials. 2020; 13(13):3014
  • Dudzik D, Iglesias Platas I, Izquierdo Renau M, Balcells Esponera C, del Rey Hurtado de Mendoza B, Lerin C, Ramón-Krauel M, Barbas C. Plasma Metabolome Alterations Associated with Extrauterine Growth Restriction. Nutrients. 2020; 12(4):1188
2019:
  • Petar Žuvela, Magdalena Skoczylas, J. Jay Liu, Tomasz Ba̧czek, Roman Kaliszan, Ming Wah Wong, and Bogusław Buszewski, Column Characterization and Selection Systems in Reversed-Phase High-Performance Liquid Chromatography, Chemical Reviews 2019 119 (6), 3674-3729
  • Buszewska-Forajta, M., Patejko, M., Macioszek, S. et al. Paraffin-Embedded Tissue as a Novel Matrix in Metabolomics Study: Optimization of Metabolite Extraction Method. Chromatographia 82, 1501–1513 (2019)
  • Yumba-Mpanga A, Struck-Lewicka W, Wawrzyniak R, Markuszewski M, Roslan M, Kaliszan R, Markuszewski MJ. Metabolomic Heterogeneity of Urogenital Tract Cancers Analyzed by Complementary Chromatographic Techniques Coupled with Mass Spectrometry. Curr Med Chem. 2019;26(1):216-231
  • Wawrzyniak R, Mpanga AY, Struck-Lewicka W, Kordalewska M, Polonis K, Patejko M, Mironiuk M, Szyndler A, Chrostowska M, Hoffmann M, Smoleński RT, Kaliszan R, Narkiewicz K, Markuszewski MJ. Untargeted Metabolomics Provides Insight into the Mechanisms Underlying Resistant Hypertension. Curr Med Chem. 2019;26(1):232-243
  • Szymanska E, Czarnomysy R, Jacyna J, Basa A, Wilczewska AZ, Markuszewski M, Winnicka K. Could spray-dried microbeads with chitosan glutamate be considered as promising vaginal microbicide carriers? The effect of process variables on the in vitro functional and physicochemical characteristics. Int J Pharm. 2019 Sep 10;568:118558
  • Kordalewska M, Macioszek S, Wawrzyniak R, Sikorska-Wiśniewska M, Śledziński T, Chmielewski M, Mika A, Markuszewski MJ. Multiplatform metabolomics provides insight into the molecular basis of chronic kidney disease. J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jun 1;1117:49-57
  • Julia Jacyna, Marta Kordalewska, Michał J. Markuszewski, Design of Experiments in metabolomics-related studies: An overview, Journal of Pharmaceutical and Biomedical Analysis, Volume 164, 2019, Pages 598-606
  • Buszewska-Forajta M, Rachoń D, Stefaniak A, Wawrzyniak R, Konieczna A, Kowalewska A, Markuszewski MJ. Identification of the metabolic fingerprints in women with polycystic ovary syndrome using the multiplatform metabolomics technique. J Steroid Biochem Mol Biol. 2019 Feb;186 176-184
  • Grochocki W, Buszewska-Forajta M, Macioszek S, Markuszewski MJ. Determination of Urinary Pterins by Capillary Electrophoresis Coupled with LED-Induced Fluorescence Detector. Molecules. 2019 Mar 24;24(6):1166
  • Wiczling P, Daghir-Wojtkowiak E, Kaliszan R, Markuszewski MJ, Limon J, Koczkowska M, Stukan M, Kuźniacka A, Ratajska M. Bayesian multilevel model of micro RNA levels in ovarian-cancer and healthy subjects. PLoS One. 2019 Aug 29;14(8):e0221764
  • Jacyna J, Wawrzyniak R, Balayssac S, Gilard V, Malet-Martino M, Sawicka A, Kordalewska M, Nowicki Ł, Kurek E, Bulska E, Patejko M, Markuszewski M, Gutknecht P, Matuszewski M, Siebert J, Kaliszan R, Markuszewski MJ. Urinary metabolomic signature of muscle-invasive bladder cancer: A multiplatform approach. Talanta. 2019 Sep 1;202:572-579


2018:

  • Patejko M, Struck-Lewicka W, Siluk D, Waszczuk-Jankowska M, Markuszewski MJ. Urinary Nucleosides and Deoxynucleosides. Adv Clin Chem. 2018;83:1-51. Epub 2017 Dec 7
  • Wiczling P. Analyzing chromatographic data using multilevel modeling. Anal Bioanal Chem. 2018 Jun;410(16):3905-3915. Epub 2018 Apr 21
  • Kubik Ł, Kaliszan R, Wiczling P. Analysis of Isocratic-Chromatographic-Retention Data using Bayesian Multilevel Modeling. Anal Chem. 2018 Nov 20;90(22):13670-13679, Epub 2018 Oct 30
  • Arlette Yumba Mpanga, Danuta Siluk, Julia Jacyna, Oliwia Szerkus, Renata Wawrzyniak, Marcin Markuszewski, Marcin Matuszewski, Roman Kaliszan, Michał Jan Markuszewski,
    Targeted metabolomics in bladder cancer: From analytical methods development and validation towards application to clinical samples, Analytica Chimica Acta, Volume 1037, Pages 188-199, 2018
  • Borsuk-De Moor A, Rypulak E, Potręć B, Piwowarczyk P, Borys M, Sysiak J, Onichimowski D, Raszewski G, Czuczwar M, Wiczling P. Population Pharmacokinetics of High-Dose Tigecycline in Patients with Sepsis or Septic Shock. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02273-17
  • Bartosińska E, Jacyna J, Borsuk-De Moor A, Kaliszan M, Kondej K, Jankau J, Renkielska A, Kruszewski WJ, Markuszewski MJ, Siluk D. Determination of tocopherols and tocotrienols in human breast adipose tissue with the use of high performance liquid chromatography-fluorescence detection. Biomed Chromatogr. 2018 Dec;32(12)
  • Szczesny D, Bartosińska E, Jacyna J, Patejko M, Siluk D, Kaliszan R. Quantitative determination of trigonelline in mouse serum by means of hydrophilic interaction liquid chromatography-MS/MS analysis: Application to a pharmacokinetic study. Biomed Chromatogr. 2018 Feb;32(2)
  • Michał J Markuszewski, K. Ciura, M. Buszewska-Forajta, J. Jacyna, M. Kordalewska, M. Szczypior, W. Połom, J. Nowakowska, M. Markuszewski, M. Matuszewski and R. Kaliszan, Fast Method for Quantitative Determination of Methylene Blue by Micellar Electrokinetic Chromatography, Biomed. J. Sci. Tech. Res. 2018; vol. 3, nr 3, s. 1-3


2017:

  • K. Ciura, A. Pawelec, M. Buszewska-Forajta, M. J. Markuszewski, J. Nowakowska, A. Prahl, B.Z Wielgomas, Sz. Dziomba, Evaluation of sample injection precision in respect to sensitivity in capillary electrophoresis using various injection modes, J. Sep. Sci. 40, 1167-1175 (2017)
  • O. Szerkus, D. Siluk, R. Kaliszan, M. J. Markuszewski, Zastosowanie planowania eksperymentów (DoE) do oceny elastyczności metody na przykładzie oznaczania cyklosporyny A w tkankach oka królików techniką UHPLC DAD, Analityka 1, 4-11 (2017)
  • O. Szerkus, W. Struck-Lewicka, M. Kordalewska, E. Bartosińska, R. Bujak, A. Borsuk, A. Bienert, A. Bartkowska-Śniatkowska, J. Warzybok, P. Wiczling, A. Nasal, R. Kaliszan, M. J. Markuszewski, D. Siluk, HPLC-MS/MS method for dexmedetomidine quantification with Design of Experiments approach: application to pediatric pharmacokinetic study, Bioanalysis 9, 395-406 (2017)
  • W. D. Sroka, B. A. B., P. Reddy, U. Roessner, P. Słupski, P. Jarzemski, A. Dąbrowska, M. J. Markuszewski, M. P. Marszałł, Determination of amino acids in urine of patients with prostate cancer and benign prostate growth, Eur. J. Cancer Prev. 26, 131-134 (2017)
  • M. Patejko, J. Jacyna, M. J. Markuszewski, Sample preparation procedures utilized in microbial metabolomics : an overview, J. Chromatogr. B 1043, 150-157 (2017)
  • O. Szerkus, J. Jacyna, A. Gibas, M. Sieczkowski, D. Siluk, M. Matuszewski, R. Kaliszan, M. J. Markuszewski, Robust HPLC-MS/MS method for levofloxacin and ciprofloxacin determination in human prostate tissue, J. Pharm. Biomed. Anal. 132, 173-183 (2017)
  • W. Grochocki, M. J. Markuszewski, J. P. Quirino, Simultaneous determination of creatinine and acetate by capillary electrophoresis with contactless conductivity detector as a feasible approach for urinary tract infection diagnosis, J. Pharm. Biomed. Anal. 137, 178-181 (2017)
  • K. Ciura, A. Pawelec, M. Buszewska-Forajta, M. J. Markuszewski, J. Nowakowska, A. Prahl, B. Wielgomas, Sz. Dziomba, Evaluation of sample injection precision in respect to sensitivity in capillary electrophoresis using various injection modes, J. Sep. Sci. 40, 1167-1175 (2017)
  • E. Daghir-Wojtkowiak, P. Wiczling, M. Waszczuk-J.Kowska, R. Kaliszan, M. J. Markuszewski, Multilevel pharmacokinetics-driven modeling of metabolomics data, Metabolomics 13, 1-13 (2017)
  • P. Wiczling, Ł. Kubik, R. Kaliszan, Maximum a posteriori Bayesian estimation of chromatographic parameters by limited number of experiments, Anal. Chem. 87, 7241-7249 (2015)
  • F. Di Lorenzo, Ł. Kubik, A. Oblak, N. I. Lore, C. Cigana, R. Lanzetta, M. Parrilli, M. A. Hamad, A. De Soyza, A. Silipo, R. Jerala, A. Bragonzi, M. A. Valvano, S. Martin-Santamaria, A. Molinaro, Activation of human Toll-like receptor 4 (TLR4)-myeloid differentiation factor 2 (MD-2) by hypoacylated lipopolysaccharide from a clinical isolate of Burkholderia cenocepacia, J. Biol. Chem. 290, 21305-21319 (2015)
  • Ł. Kubik, W. Struck-Lewicka, R. Kaliszan, P. Wiczling, Simultaneous determination of hydrophobicity and dissociation constant for a large set of compounds by gradient reverse phase high performance liquid chromatography-mass spectrometry technique, J. Chromatogr. A 1416, 31-37 (2015)
  • N. P. Milosevic, V. Kojic, J. Curcic, D. Jakimov, N. Milic, N. Banjac, G. Uscumlic, R. Kaliszan, Evaluation of in silico pharmacokinetic properties and in vitro cytotoxic activity of selected newly synthesized N-succinimide derivatives, J. Pharm. Biomed. Anal. 137, 252-257 (2017)


2016:

  • T. Frąckowiak, Konferencja naukowo-szkoleniowa w Birmingham, Gazeta AMG 26, 37 (2016)
  • T. Frąckowiak, M. Prusak, A. Radwańska, Dylematy aptekarskiego sumienia – trochę głębiej…, Przegl. Farm. 253, 22-25 (2016)
  • Z. Heleniak, M. Cieplińska, M. Pryczkowska, T. Szychliński, E. Bartosińska, H. Wiatr, H. Kotłowska, M. Jakimowicz-Tylicka, L. Tylicki, B. Rutkowski, A. Dębska-Ślizień, Using analgesics including nonsteroidal anti-inflammatory drugs in patients with chronic kidney disease (CKD 1-4) and after kidney transplantation : one center experiences, Transplantation 100, 630 (2016)
  • Ł. Kubik, P, Wiczling, Quantitative structure-(chromatographic) retention relationship models for dissociating compounds, J. Pharm. Biomed. Anal. 127, 176-183 (2016)
  • W. Grochocki, M. J. Markuszewski, J. P. Quirino, Anal. Methods 8, 1216-1221 (2016)
  • D. Siluk, M. J. Markuszewski, Jubileusz Profesora R. Kaliszana, Analityka 4, 70-71 (2016)
  • O. Szerkus, A. Yumba Mpanga, M. J. Markuszewski, R. Kaliszan, D. Siluk, Optimization of the electrospray lonization source with the use of the design of experiments approach for the LC-MS-MS determination of selected metabolites in human urine, Curr. Trends Mass Spectrom. 14, 8-16 (2016)
  • K. Ciura, P. Kowalski, J. Nowakowska, M. Markuszewski, T. Bączek, Sz. Dziomba, Sweeping of hydrophobic amines under inhomogeneous electric field and low surfactant concentration in micellar electrokinetic chromatography, Electrophoresis 37, 1161-1165 (2016)
  • R. Bujak, E. Daghir-Wojtkowiak, R. Kaliszan, M. J. Markuszewski, PLS-based and regularization-based methos for the selection of relevant variables in non-targeted metabolomics data, Front. Mol. Biosci. 3, 1-10 (2016)
  • W. Grochocki, M. J. Markuszewski, J. P. Quirino, Three-step stacking by field-enhanced sample injection, sweeping, and micelle to solvent stacking in capillary electrophoresis: anionic analytes, J. Chromatogr. A 1442, 140-143 (2016)
  • O. Szerkus, J. Jacyna, P. Wiczling, A. Gibas, M. Sieczkowski, D. Siluk, M. Matuszewski, R. Kaliszan, M. J. Markuszewski, Ultra-high performance liquid chromatographic determination of levofloxacin in human plasma and prostate tissue with use of experimental design optimization procedures, J. Chromatogr. B 1029, 48-59 (2016)
  • M. J. Markuszewski, In honor of the 70th birthday of Professor R. Kaliszan, J. Pharm. Biomed. Anal. 127, 1-2 (2016)
  • P. Kośliński, E. Daghir-Wojtkowiak, P. Szatkowska-Wandas, M. Markuszewski, M. J. Markuszewski, The metabolic profiles of pterin compounds as potential biomarkers of bladder cancer : integration of analytical-based approach with biostatistical methodology, J. Pharm. Biomed. Anal. 127, 256-262 (2016)
  • R. Bujak, R. Gadzała-Kopciuch, A. Nowaczyk, J. Raczak-Gutknecht, M. Kordalewska, W. Struck-Lewicka, M. Waszczuk-J.Kowska, E. Tomczak, M. Kaliszan, B. Buszewski, M. J. Markuszewski, New sorbent materials for selective extraction of cocaine and benzoylecgonine from human urine samples, J. Pharm. Biomed. Anal. 120, 397-401 (2016)
  • J. Nowakowska, K. Ciura, P. Kawczak, T. Bączek, M. J. Markuszewski, Quantitative structure-retention relationships of some steroid and phenanthrene derivatives on cyano-, reversed-phase, and normal-phase thin-layer chromatography stationary phases, JPC – J. Planar Chromatogr.-Mod. TLC 29, 165-175, (2016)
  • J. Nowakowska, K. Ciura, W. Struck-Lewicka, P. Pikul, M. J. Markuszewski, P. Kawczak, Study of the chromatographic behavior of selected steroid hormones on aluminium oxide plates based on quantitative structure-retention relationships, JPC – J. Planar Chromatogr.-Mod. TLC 29, 113-120 (2016)
  • K. Ciura, J. Nowakowska, K. Rudnicka-Litka, P. Kawczak, T. Bączek, M. J. Markuszewski, The study of salting-out thin-layer chromatography and their application on QSRR/QSAR of some macrolide antibiotics, Mon. Chem. 147, 301-310 (2016)
  • R. Bujak, J. Mateo, I. Blanco, J. L. Izquierdo-García, D. Dudzik, M. J. Markuszewski, V. I. Peinado, M. Laclaustra, J. A. Barberá, C. Barbas, J. Ruiz-Cabello, New biochemical insights into the mechanisms of pulmonary arterial hypertension in humans, PLoS ONE 11, 1-14 (2016)
  • R. Bujak, R. Gadzała-Kopciuch, A. Nowaczyk, J. Raczak-Gutknecht, M. Kordalewska, W. Struck-Lewicka, M. J. Markuszewski, B. Buszewski, Selective determination of cocaine and its metabolite benzoylecgonine in envirinmental samples by newly developed sorbent materials, Talanta 146, 401-409 (2016)
  • P. Wiczling, R. Kaliszan, How much can we learn from a single chromatographic experiment?: a Bayesian perspective, Anal. Chem. 88, 997-1002 (2016)
  • P. Wiczling, K. Bieda, K. Przybyłowski, R. Hartmann-Sobczyńska, A. Borsuk, J. Matysiak, Z. J. Kokot, P. Sobczyński, E. Grześkowiak, A. Bienert, Pharmacokinetics and pharmacodynamics of propofol and fentanyl in patients undergoing abdominal aortic surgery : a study of pharmacodynamic drug-drug interactions, Biopharm. Drug Dispos. 37, 252-263 (2016)
  • P. Smuszkiewicz, P. Wiczling, K. Przybyłowski, A. Borsuk, I. Trojanowska, M. Paterska, J. Matysiak, Z. Kokot, E. Grześkowiak, A. Bienert, The pharmacokinetics of propofol in ICU patients undergoing long-term sedation, Biopharm. Drug Dispos. 37, 456-466 (2016)
  • Jeremie H. Estepp, C. Melloni, C. D. Thornburg, P. Wiczling, Z. Rogers, J. A. Rothman, N. S. Green, R. Liem, A. M. Brandow, S. E. Crary, T. H. H.oward, M. H. Morris, A. Lewandowski, U. Garg, W. J. Jusko, K. A. Neville, Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia, J. Clin. Pharmacol. 56, 298-306 (2016)
  • A. Bartkowska-Śniatkowska, A. Bienert, P. Wiczling, J. Rosada-Kurasińska, M. Zielińska, J. Warzybok, A. Borsuk, D. Tibboel, R. Kaliszan, E. Grześkowiak, Pharmacokinetics of sufentanil during long-term infusion in critically ill pediatric patients, J. Clin. Pharmacol. 56, 109-115 (2016)
  • A. Bartkowska-Śniatkowska, P. Wiczling, M. Juzwa-Sobieraj, E. Kałużna, B. Świątek-Kościelna, A. Bienert, A. Borsuk, A. Tezyk, J. Rosada-Kurasinska, D. Januszkiewicz-Lewandowska, The pharmacokinetics of midazolam and 1-OH-midazolam during oral premedication in paediatric patients, J. Med. Sci. 85, 73-82 (2016)
  • P. Wiczling, A. Bartkowska-Śniatkowska, O. Szerkus, D. Siluk, J. Rosada-Kurasińska, J. Warzybok, A. Borsuk, R. Kaliszan, E. Grześkowiak, A. Bienert, The pharmacokinetics of dexmedetomidine during long-term infusion in critically ill pediatric patients : a Bayesian approach with informative priors, J. Pharmacokinet. Pharmacodyn. 43, 315-324 (2016)
  • R. Kaliszan, Egalitaryzm nade wszystko, Forum Akadem. 2, 28 (2016)
  • A. Viapiana, W. Struck-Lewicka, P. Konieczyński, M. Wesołowski, R. Kaliszan, An approach based on HPLC-fingerprint and chemometrics to quality consistency evaluation of Matricaria chamomilla L. commercial samples, Front. Plant Sci. 7, 1561 (2016)
  • M. Buszewska-Forajta, M. Kordalewska, E. Bartosińska, D. Siluk, R. Kaliszan, Compound identification in metabolomics: a study with the use of two different GC data processing systems, J. Anal. Chem. 71, 646-652 (2016)
  • D. Świeczkowski, J. Krysiński, P. Merks, D. Siluk, Pharmaceutical care in the opinion of physicians and pharmacists Pomeranian Province, Farm. Pol. 72, 201-210 (2016)
  • E. Bartosińska, M. Buszewska-Forajta, D. Siluk, GC-MS and LC-MS approaches for determination of tocopherols and tocotrienols in biological and food matrices, J. Pharm. Biomed. Anal. 127, 156-169 (2016)
  • W. Wołyniec, W. Ratkowski, R. Urbański, M. Bartoszewicz, Z. Wołyniec, D. Siluk, K. Zorena, M. Renke, Stężenie KIM-1, ale nie stężenie NGAL jest podwyższone w moczu po krótkim, maksymalnym wysiłku, Nefrol. Dializoter. Pol. 20, 163 (2016)
  • W. Wołyniec, W. Ratkowski, R. Urbański, M. Bartoszewicz, Z. Wołyniec, D. Siluk, K. Zorena, M. Renke, Urinary KIM-1 but not urinary NGAL is increased after short maximal exercise, Nephrol. Dial. Transplant. 31, 149 (2016)


2015:

  • A. Plenis, T. Bączek, J. Szulfer, M. Markuszewski, New materials applied for the stationary phases in view of the optimized HPLC and UHPLC column classification system used in the pharmaceutical analysis, Adv. Mater. Res. 1120-1121, 1404-1412 (2015)
  • E. Daghir-Wojtkowiak, W. Struck-Lewicka, M. Waszczuk-J.Kowska, M. Markuszewski, R. Kaliszan, M. J. Markuszewski, Statistical-based approach in potential diagnostic application of urinary nucleosides in urogenital tract cancer, Biomark. Med. 9, 577-595 (2015)
  • W. Grochocki, M. J. Markuszewski, J. P. Quirino, Multidimensional capillary electrophoresis, Electrophoresis 36, 135-143 (2015)
  • H. Wosicka-Frąckowiak, K. Cal, J. Stefanowska, E. Główka, M. Nowacka, W. Struck-Lewicka, B.J. Govedarica, M. Pasikowska, R. Dębowska, T. Jesionowski, S. Srcic, M. J. Markuszewski, Roxithromycin-loaded lipid nanoparticles for follicular targeting, Int. J. Pharm. 495, 807-815 (2015)
  • K. Ciura, J. Nowakowska, P. Pikul, W. Struck-Lewicka, M. J. Markuszewski, A comparative quantitative structure-retention relationships study for lipophilicity determination of compounds with a phenanthrene skeleton on cyano-, reversed phase-, and normal phase-thin layer chromatography stationary phases, J. AOAC Int. 98, 345-353 (2015)
  • E. Daghir-Wojtkowiak, P. Wiczling, Sz. Bocian, Ł. Kubik, P. Kośliński, B. Buszewski, R. Kaliszan, M. J. Markuszewski, Least absolute shrinkage and selection operator and dimensionality reduction techniques in quantitative structure retention relationship modeling of retention in hydrophilic interaction liquid chromatography, J. Chromatogr. A 1403, 54-62 (2015)
  • W. Grochocki, M. J. Markuszewski, J. P. Quirino, Three-step stacking of cationic analytes by field-enhanced sample injection, sweeping, and micelle to solvent stacking in capillary electrophoresis, J. Chromatogr. A 1424, 111-117 (2015)
  • R. Bujak, K. Polonis, W. Struck-Lewicka, A. Szyndler, M. Chrostowska, M. Hoffman, A. Yumba-Mpanga, M. Kordalewska, R. Kaliszan, K. Narkiewicz, M. J. Markuszewski, Untargeted metabolomics with LC-TOF/MS in studies on mechanisms underlying early vascular ageing, J. Hypertens. 33, 222-223 (2015)
  • R. Bujak, W. Struck-Lewicka, M. Kaliszan, R. Kaliszan, M. J. Markuszewski, Blood-brain barrier permeability mechanisms in view of quantitative structure-activity relationships (QSAR), J. Pharm. Biomed. Anal. 108, 29-37 (2015)
  • R. Bujak, W. Struck-Lewicka, M. J. Markuszewski, R. Kaliszan, Metabolomics for laboratory diagnostics, J. Pharm. Biomed. Anal. 113, 108-120 (2015)
  • M. Kordalewska, M. J. Markuszewski, Metabolomics in cardiovascular diseases, J. Pharm. Biomed. Anal. 113, 121-136 (2015)
  • W. Struck-Lewicka, M. Kordalewska, R. Bujak, A. Yumba Mpanga, Marcin Markuszewski, J. Jacyna, Marcin Matuszewski, R. Kaliszan, M. J. Markuszewski, Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: a pilot study, J. Pharm. Biomed. Anal. 111, 351-361 (2015)
  • A. Bienert, K. Wawrzyniak, P. Wiczling, K. Przybyłowski, Z. J. Kokot, J. Matysiak, A. Pachutko, M. Józefowicz, K. Kusza, E. Grześkowiak, Melatonin and clonidine premedication has similar impact on the pharmacokinetics and pharmacodynamics of propofol target controlled-infusions, J. Clin. Pharmacol. 55, 307-316 (2015)
  • K. Przybyłowski, J. Tyczka, D. Szczesny, A. Bienert, P. Wiczling, K. Kut, E. Plenzler, R. Kaliszan, E. Grześkowiak, Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery, J. Pharmacokinet. Pharmacodyn. 42, 111-122 (2015)
  • B. Pilarski, R. Kaliszan, D. Wyrzykowski, J. Młodzianowski, A. Balińska, General analytical procedure for determination of acidity parameters of weak acids and bases, J. Anal. Methods Chem. 2015, 1-8 (2015)
  • M. Buszewska-Forajta, D. Siluk, E. Daghir-Wojtkowiak, A. Sejda, D. Staśkowiak, W. Biernat, R. Kaliszan, Studies of the effect of grasshopper abdominal secretion on wound healing with the use of murine model, J. Ethnopharmacol. 176, 413-423 (2015)
  • M. Kaczmarek, A. Buciński, M. P. Marszałł, A. Badura, R. Kaliszan, Thermodynamic and QSRR modeling of HPLC retention on modern stationary phases, J. Liq. Chrom. Rel. Technol. 38, 62-67 (2015)
  • M. Buszewska-Forajta, R. Bujak, A. Yumba-Mpanga, D. Siluk, R. Kaliszan, GC/MS technique and AMDIS software application in identification of hydrophobic compounds of grasshoppers’ abdominal secretion (Chorthippus spp.), J. Pharm. Biomed. Anal. 102, 331-339 (2015)
  • J. Raczak-Gutknecht, T. Frąckowiak, A. Nasal, P. Kowalski, A. Kornicka, F. Sączewski, R. Kaliszan, Evaluation of pharmacological interactions of new imidazoline derivatives marsanidine and 7-methylmarsanidine with alpha2-adrenergic receptors using rat mydriasis model, Pharmacol. Rep. 67, 35-36 (2015)
  • J. Długokęcka, S. Szynaka, K. Wojtalik, A. Nasal, A. Radwańska, R. Kaliszan, Metrazoline, BU224, BU226 and BU239 act on isolated rat heart atria via I2-imidazoline receptors : are the ATP-sensitive potassium (KATP) channels also involved?, Pharmacol. Rep. 67, 20 (2015)
  • J. Raczak-Gutknecht, T. Frąckowiak, A. Nasal, A. Kornicka, F. Sączewski, P. Kowalski, R. Kaliszan, Study on the mechanism of mydriatic activity of imidazoline derivatives dexmedetomidine, marsanidine and 7-methylmarsanidine in rats : are alpha2D-adrenoceptors engaged?, Pharmacol. Rep. 67, 35 (2015)
  • E. Bartosińska, D. Siluk, Human adipose tissue pretreatment method development for tocopherols’ and tocotrienols’ targeted metabolomics in breast cancer disease, Acta. Biochim. Pol. 62, 31 (2015)
  • K. Kunicka, K. Polonis, E. Świerblewska, M. Hoffmann, J. Wolf, A. Szyndler, E. Daghir-Wojtkowiak, O. Melander, T. Hedner, K. Narkiewicz, Single nucleotide polymorphisms contributes to left ventricular diastolic function in hypertensive subjects, J. Hypertens. 33, 517 (2015)
  • P. Gutknecht, B. G. Trzeciak, M. Pietrzykowska, M. Reiwer-Gostomska, A. Molisz, J. Raczak-Gutknecht, K. Nowicka-Sauer, J. Siebert, Knowledge of patients about gastroesophageal reflux disease, Forum Med. Rodz. 9, 291-293 (2015)


2014:

  • Wiczling P., Struck-Lewicka W., Kubik Ł., Siluk D., Markuszewski M.J., Kaliszan R. The simultaneous determination of hydrophobicity and dissociation constant by liquid chromatography-mass spectrometry, J. Pharm. Biomed. Anal. vol. 94, 180-187 (2014).
  • Mason R.P., Jacob R.F., Corbalan J.J., Kaliszan R., Malinski T. Amlodipine increased endothelial nitric oxide and decreased nitroxidative stress disproportionately to blood pressure changes, Am.J. Hypertens., 3, 482-488 (2014).
  • Daghir-Wojtkowiak E., Studzińska S., Buszewski B., Kaliszan R., Markuszewski M.J. Quantitative structure-retention relationships of ionic liquid cations in characterization of stationary phases for HPLC, Anal. Methods, 6, 1189-1196 (2014).
  • Markuszewski M.J., Kaliszan R. Using bioanalysis for cancer diagnosis and prognosis, Bioanalysis, 7, 907-909 (2014).
  • Szerkus O., Wolska E., Struck-Lewicka W., Siluk D., Radwańska A., Wiczling P., Chorążewicz J., Sznitowska M., Markuszewski M.J., Kaliszan R. Development and validation of UHPLC method for the determination of cyclosporine A in biological samples, Biomed. Chromatogr., 6, 802-809 (2014).
  • Wiczling P., Krzyzanski W., Żychlińska N., Lewandowski K., Kaliszan R. The quantification of reticulocyte maturation and neocytolysis in normal and erythropoietin stimulated rats, Biopharm. Drug Dispos., 6, 330-340 (2014).
  • Buszewska-Forajta M., Struck-Lewicka W., Bujak R., Siluk D., Kaliszan R. Determination of water-soluble components of abdominal secretion of grasshopper (Chorthippus spp.) by GC/MS/MS in search for potential wound healing agents, Chromatographia, 15-16, 1091-1102 (2014).
  • Szultka M., Buszewska-Forajta M., Kaliszan R., Buszewski B. Determination of ascorbic acid and its degradation products by high-performance liquid chromatography-triple quadrupole mass spectrometry, Electrophoresis, 4, 585-592 (2014).
  • Raczak-Gutknecht J., Frąckowiak T., Nasal A., Rietz J., Paszek M., Buszewska-Forajta M., Kaliszan R. Effect of the reference imidazoline drugs, clonidine and rilmenidine, on rat eye pupil size confirms the decisive role of α2-adrenoceptors on mydriasis, Int. J. Pharmacol.; 8, 470-478 (2014).
  • Makowska J., Szczesny D., Lichucka A., Giełdoń A., Chmurzyński L., Kaliszan R. Preliminary studies on trigonelline as potential anti-Alzheimer disease agent: determination by hydrophilic interaction liquid chromatography and modeling of interactions with beta-amyloid, J. Chromatogr. B, vol. 968, 101-104 (2014).
  • Struck-Lewicka W., Kaliszan R., Markuszewski M.J. Analysis of urinary nucleosides as potential cancer markers determined using LC-MS technique, J. Pharm. Biomed. Anal., vol. 101, 50-57 (2014).
  • Kośliński P., Jarzemski P., Markuszewski M.J., Kaliszan R. Determination of pterins in urine by HPLC with UV and fluorescent detection using different types of chromatographic stationary phases (HILIC, RP C8, RP C18), J. Pharm. Biomed. Anal., vol. 91, 37-45 (2014).
  • Buszewska-Forajta M., Siluk D., Struck-Lewicka W., Raczak-Gutknecht J., Markuszewski M.J., Kaliszan R. Identification of lipid fraction constituents from grasshopper (Chorthippus spp.) abdominal secretion with potential activity in wound healing with the use of GC-MS/MS technique, J. Pharm. Biomed. Anal., vol. 89, 56-66 (2014).
  • N. P. Milošević, S. Z. Stojanović, K. Penov-Gasi, N. Perišić-Janjić, Kaliszan R. Reversed- and normal-phase liquid chromatography in quantitative structure retention-property relationships of newly synthesized seco-androstene derivatives, J. Pharm. Biomed. Anal., vol. 88, 636-642 (2014).
  • Bienert A., Płotek W., Wiczling P., Kostrzewski B., Kamińska A., Billert H., Szczesny D., Żaba C., Teżyk A., Buda K., Bednarek E., Kaliszan R., Grześkowiak E. The influence of the time of day on midazolam pharmacokinetics and pharmacodynamics in rabbits, Pharmacol. Rep., 1, 143-152 (2014).
  • Bartkowska-Śniatkowska A., Bienert A., Wiczling P., Owczarek M., Rosada-Kurasińska J., Grześkowiak M., Matysiak J., Kokot Z.J., Kaliszan R., Grześkowiak E. Pharmacokinetics and pharmacodynamics of propofol in children undergoing different types of surgeries, Pharmacol. Rep., 5, 821-829 (2014).


2013:

  • Kaliszan, R. Quantitative Structure Property (Retention) Relationships in Liquid Chromatography, Liquid Chromatography: Fundamentals and Instrumentation, 385-405 (2013).
  • Cighetti R., Ciaramelli C., Sestito S.E., Zanoni I., Kubik Ł., Arda-Freire A., Calabrese V., Granucci F., Jerala R., Martin-Santamaria S., Jimenez-Barbero J., Peri F. Modulation of CD14 and TLR4-MD-2 activities by a synthetic lipid A mimetic, Chembiochem, 2, 250-258 (2013).
  • Goryński K., Bojko B., Nowaczyk A., Buciński A., Pawliszyn J., Kaliszan R. Quantitative structure-retention relationship models for prediction of high performance liquid chromatography retention time of small molecules: Endogenous metabolites and banned compounds, Anal. Chim. Acta vol. 797, 13-19 (2013).
  • Konieczna L., Belka M., Bączek T., Ruszkowski M., Struck W., Markuszewski M.J., Kaliszan R., Markuszewski M. Advanced assessment of the endogenous hormone level as a potential biomarker of the urogenital tract cancer, Comb. Chem. High Throughput Screen. 6, 463-472 (2013).
  • Marszałł M.P., Proszowska A., Buciński A., Kaliszan R. Affinity chromatography method for determination of binding of drugs to melanin and evaluation of side effect potential of antipsychotic agents, Curr. Pharm. Anal. 2, 131-138 (2013).
  • Struck W. Siluk D., Yumba-Mpanga A., Markuszewski M., Kaliszan R., Markuszewski M.J. Liquid chromatography tandem mass spectrometry study of urinary nucleosides as potential cancer markers, J. Chromatogr. A, vol. 1283, 122-131 (2013).
  • Marszałł M.P., Sroka W.D., Balinowska A., Mieszkowski D., Koba M., Kaliszan R. Ionic liquids as mobile phase additives for feasible assay of naphazoline in pharmaceutical formulation by HPTLC-UV-densitometric method, J. Chromatogr. Sci., vol. 51, 560-565 (2013).
  • Perisic-Janjic N., Kaliszan R., Milosevic N., Uscumlic G., Banjac N. Chromatographic retention parameters in correlation analysis with in silico biological descriptors of a novel series of N-phenyl-3-methyl succinimide derivatives, J. Pharm. Biomed. Anal., vol. 72, 65-73 (2013).
  • Konieczna L., Bączek T., Belka M., Fel A., Markuszewski M., Struck W., M.J. Markuszewski, Kaliszan R. Steroid profiles as potential biomarkers in patients with urogenital tract cancer for diagnostic investigations analyzed by liquid chromatography coupled to mass spectrometry J. Pharm. Biomed. Anal., vol. 73, 108-115 (2013).
  • Nikolic K., Filipic S., Smoliński A., Kaliszan R., Agbaba D. Partial least square and hierarchical clustering in ADMET modeling: prediction of blood – brain barrier permeation of α-adrenergic and imidazoline receptor ligands J. Pharm. Pharm. Sci., 4, 622-647 (2013).
  • Bienert A., Bartkowska-Śniatkowska A., Wiczling P., Rosada-Kurasińska J., Grześkowiak M., Żaba Cz., Teżyk A., Sokołowska A., Kaliszan R., Grześkowiak E. Assessing circadian rhythms during prolonged midazolam infusion in the pediatric intensive care unit (PICU) children, Pharmacol. Rep., vol. 65, 107-121 (2013).
  • Raczak-Gutknecht J., Frąckowiak T., Nasal A., Kaliszan R. Mydriasis model in rats as a simple system to evaluate α2-adrenergic activity of the imidazol(in)e compounds, Pharmacol. Rep., 2, 305-312 (2013).


2012:

  • Wiczling P., Nasal A., Kubik Ł., Kaliszan R. A new pH/organic modifier gradient RP HPLC method for convenient determination of lipophilicity and acidity of drugs as applied to established imidazoline agents, European Journal of Pharmaceutical Sciences, 47, 1-5 (2012).
  • Struck W., Wiczling P., Waszczuk-Jankowska M., Kaliszan, R., Markuszewski, M.J. New supervised alignment method as a preprocessing tool for chromatographic data in metabolomic studies, Journal of Chromatography A, 1256, 150-159 (2012).
  • Wiczling P., Bienert A., Sobczynski P., Hartmann-Sobczynska R., Bieda K., Marcinkowska A., Malatynska M., Kaliszan R. Grzeskowiak, E. Pharmacokinetics and pharmacodynamics of propofol in patients undergoing abdominal aortic surgery, Pharmacological Reports, 64, 113-122 (2012).
  • Di Tullio M., MacCallini C., Ammazzalorso A., Giampietro L., Amoroso R., De Filippis B., Fantacuzzi M., Wiczling P., Kaliszan R. QSAR, QSPR and QSRR in terms of 3-D-MoRSE descriptors for in silico screening of clofibric acid analogues Molecular Informatics, 31, 453-458 (2012).
  • Waszczuk-Jankowska M., Markuszewski M.J., Markuszewski M., Kaliszan R. Comparison of RP-HPLC columns used for determination of nucleoside metabolic patterns in urine of cancer patients, Bioanalysis, 4, 1185-1194 (2012).
  • Konieczna L., Baczek T., Belka M., Fel A., Markuszewski, M., Struck W., Markuszewski M., Kaliszan R. Steroid profiles as potential biomarkers in patients with urogenital tract cancer for diagnostic investigations analyzed by liquid chromatography coupled to mass spectrometry, Journal of Pharmaceutical and Biomedical Analysis, w druku, (2012) .
  • Struck W., Waszczuk-Jankowska M., Kaliszan R., Markuszewski M.J. The state-of-the-art determination of urinary nucleosides using chromatographic techniques “hyphenated” with advanced bioinformatic methods, Analytical and Bioanalytical Chemistry, 401, 2039-2050 (2012).


2011:

  • Struck W., Waszczuk-Jankowska M., Kaliszan R., Markuszewski M.J. The state-of-the-art determination of urinary nucleosides using chromatographic techniques “hyphenated” with advanced bioinformatic methods, Analytical and Bioanalytical Chemistry, 401, 2039-2050 (2011).
  • Kaliszan R., Wiczling P. Gradient reversed-phase high-performance chromatography of ionogenic analytes, TrAC – Trends in Analytical Chemistry, 30, 1372-1381 (2011)
  • Perisic-Janjic N., RKaliszan R., Wiczling P., Milosevic N., Uscumlic G., Banjac N., Reversed-phase TLC and HPLC retention data in correlation studies with in silico molecular descriptors and druglikeness properties of newly synthesized anticonvulsant succinimide derivatives, Molecular Pharmaceutics, 8, 555-563 (2011).
  • Kaliszan R., Wiczling P., Markuszewski M.J., Al-Haj M.A., Thermodynamic vs. extrathermodynamic modeling of chromatographic retention, Journal of Chromatography A, 1218, 5120-5130 (2011)
  • Marszall M. P., Bucinski A., Gorynski K., Proszowska A., Kaliszan R., Magnetic beads method for determination of binding of drugs to melanin, ournal of Chromatography A, 1218, 229-236 (2011).


2010:

  • Daghir E., Markuszewski M.J.: Disposition of drugs of abuse and their metabolites in wastewater as a method of the estimation of drug consumption, Current Drug Metabebolism 11, 629-638 (2010)
  • Bartusik D., Tomanek B., Siluk D., Kaliszan R.: 19F MRI of 3D CEM cells to study the effects of tocopherols and tocotrienols, Journal of Pharmaceutical and Biomedical Analysis 53, 599-602 (2010)
  • Szymańska E., Markuszewski M.J., Markuszewski M., Kaliszan R.: Altered levels of nucleoside metabolite profiles in urogenital tract cancer measured by capillary electrophoresis, Journal of Pharmaceutical and Biomedical Analysis 53, 1305-1312 (2010)
  • Markuszewski M.J., Struck W., Waszczuk-Jankowska M., Kaliszan R.: Metabolomic approach for determination of urinary nucleosides as potential tumor markers using electromigration techniques, Electrophoresis 31, 2300-2310 (2010)
  • Bartusik D., Tomanek B., Siluk D., Kaliszan R: (19)F MRI of 3D CEM cells to study the effects of tocopherols and tocotrienols. Journal of Pharmaceutical and Biomedical Analysis (2010).
  • Bodzioch K., Durand A., Kaliszan R., Baczek T. and Vander Heyden Y.: Advanced QSRR modeling of peptides behavior in RPLC. Talanta 81, 1711-1718 (2010).
  • Grabowska I., Radecka H., Burza A., Radecki J., Kaliszan M., Kaliszan R.: Association constants of pyridine and piperidine alkaloids to amyloid beta peptide determined by electrochemical impedance spectroscopy. Current Alzheimer Research 7, 165-172 (2010).
  • Kawczak P., Vander Heyden Y., Nasal A., Baczek T., Drabczynska A., Kiec-Kononowicz K., Kaliszan R.: Micellar liquid chromatography for lipophilicity determination of new biologically active 1,3-purinodiones. Journal of Separation Science 33, 1546-1557 (2010).
  • Macur K., Baczek T., Kaliszan R., Temporini C., Corana F., Massolini G., Grzenkowicz-Wydra J., Obuchowski M.: Correctness of protein identifications of bacillus subtilis proteome with the indication on potential false positive peptides supported by predictions of their retention times. Journal of Biomedicine and Biotechnology 718142 (online) (2010).
  • Molikova M., Markuszewski M.J., Kaliszan R., Jandera P.: Chromatographic behaviour of ionic liquid cations in view of quantitative structure-retention relationship. Journal of Chromatography A 1217, 1305-1312 (2010).
  • Wiczling P., Kaliszan R,: pH Gradient as a tool for the separation of ionizable analytes in reversed-phase high-performance chromatography. Analytical Chemistry 82, 3692-3698 (2010).
  • Wiczling P., Kaliszan R,: Retention time and peak width in the combined pH/organic modifier gradient high performance liquid chromatography. Journal of Chromatography A 1217, 3375-3381 (2010).
  • Krzyzanski W., Wiczling P., Lowe P., Pigeolet E., Fink M., Berghout A., Balser S., Population Modeling of Filgrastim PK/PD in Healthy Adults Following Intravenous and Subcutaneous Administrations, The Journal of Clinical Pharmacology, 50, 101S-112S (2010)
  • Bienert A., Kusza K., Wawrzyniak K., Grześkowiak E., Kokot Z., Matysiak J., Grabowski T., Wolc A., Wiczling P., Regulski M.: Assessing circadian rhythms in propofol PK and PD during prolonged infusion in ICU patients, Journal Pharmacokinetics and Pharmacodynamics, 37:289-304 (2010)
  • Hale G., Rebello P., al Bakir I., Bolam E., Rosenzweig M., Carmody F., Wiczling P., Jusko W.J., Keymeulen B., Chatenoud L., Pipeleers D., Waldmann H., Pharmacokinetics and antibody responses to a CD3 antibody used in the treatment of Type I diabetes, Journal of Clinical Pharmacology, 50: 1238-1248 (2010)
  • Wiczling P., Rosenzweig M., Vaickus L., Jusko W.J., Pharmacokinetics and Pharmacodynamics of Anti-CD3 Monoclonal Antibody, Otelixizumab (TRX4), in Patients with Psoriasis and with Type 1 Diabetes Mellitus, Journal of Clinical Pharmacology, 50: 494-506 (2010)


2009

  • Baczek T., Kaliszan R.: Predictions of peptides’ retention times in reversed-phase liquid chromatography as a new supportive tool to improve protein identification in proteomics. Protemics 9, 835-847 (2009).
  • Kaliszan R., Markuszewski M.J.: Preface. Journal of Pharmaceutical and Biomedical Analysis 50, 549 (2009).
  • Bodzioch K., Bączek T., Kaliszan R., Heyden Y.V.: The molecular descriptor log SumAA and its alternatives in QSRR models to predict the retention of peptides. Journal of Pharmaceutical and Biomedical Analysis 50, 563-569 (2009).
  • Szymańska E., Markuszewski M.J., Heyden Y.V., Kaliszan R.: Efficient recovery of electrophoretic profiles of nucloside metabolites from urine samples by multivariate curve resolution. Electrophoresis 30, 3573-3581 (2009).
  • Wiczling P., Lowe P., Pigeolet E., Luedicke F., Balser S., Krzyzanski W., Population Modeling of Filgrastim Pharmacokinetics in Healthy Adults following Intravenous and Subcutaneous Administrations, Clinical Pharmacokinetics, 48: 817-826 (2009).
  • Wiczling P., Ait-Oudhia S., Krzyzanski W.. Flow cytometric analysis of reticulocyte maturation after erythropoietin administration in rats, Cytometry A, 75: 584-592 (2009).


2008

  • Baczek T., Walijewski L., Kaliszan R.: pH gradient reversed-phase liquid chromatography as a fractionation tool for the separation of peptides. Talanta 75, 76-82 (2008).
  • Wiczling P., Kaliszan, R.: Influence of pH on retention in linear organic modifier gradient RP HPLC Analytical Chemistry 80(20), 7855-7861 (2008).
  • Wiczling P., Waszczuk-Jankowska M., Markuszewski M.J., Kaliszan R.: The application of gradient reversed-phase high-performance liquid chromatography to the pKa and log kw determination of polyprotic analytes. Journal of Chromatography A, 1214, 109-114 (2008).
  • Baczek T., Bodzioch K., Michalska E., Kaliszan R.: Predictions of reversed-phase gradient elution LC separations supported by QSRR. Chromatographia 68, 161-166 (2008).
  • Wiczling P., Krzyzanski W.: Flow cytometric assessment of homeostatic aging of reticulocytes in rats. Experimental Hematology. 36:119-127 (2008)


2007

  • Michel M., Baczek T., Studzinska S., Bodzioch K., Jonsson T., Kaliszan R., Buszewski B.: Comparative evaluation of high-performance liquid chromatography stationary phases used for the separation of peptides in terms of quantitative structure-retention relationships. Journal of Chromatography A 1175, 49-54 (2007).
  • Szymanska E., Markuszewski M.J., Capron X., van Nederkassel A.-M., Vander Heyden Y., Markuszewski M., Krajka K., Kaliszan R.: Evaluation of different warping methods for the analysis of CE profiles of urinary nucleosides. Electrophoresis 28, 2861-2873 (2007).
  • Bucinski A., Romaszko J., Kaliszan R., Targonski R. Romaszko E., Zakrzewski A., Rychlicka M.: Can homelossness be treated as a defined risk for cardiobascular diseases? Zdrowie Publiczne, 117, 324-329 (2007).
  • Baczek T., Temporini C., Perani E., Massolini G., Kaliszan R.: Identification of peptides in proteomics supported by prediction of peptide retention by means of quantitative structure-retention relationships. Acta Chromatographica 18, 72-92 (2007).
  • Szymanska E., Markuszewski M.J., Bodzioch K., Kaliszan R.: Development and validation nucleosides and creatinine assay by capillary electrophoresis with solid phase extraction. Journal of Pharmaceutical and Biomedical Analysis 44, 1118-1126 (2007).
  • Szymanska I., Radecka H., Radecki J., Kaliszan R.: Electrochemical impedance spectroscopy for study of amyloid beta-peptide interactions with (–)nicotine ditartrate and (–)cotinine. Biosensors and Bioelectronics 22, 1955-1960 (2007).
  • Szymanska E., Markuszewski M.J., Capron X., van Nederkassel A.-M., Vander Heyden Y., Markuszewski M., Krajka K., Kaliszan R.: Increasing conclusiveness of metabonomic studies by cheminformatic preprocessing of capillary electrophoresis data on urinary nucleoside profiles.
    Journal of Pharmaceutical and Biomedical Analysis 43, 413-420 (2007).


2006

  • Marszall M.P., Markuszewski M.J., Kaliszan R.: Separation of nicotinic acid and its structural isomers using 1-ethyl-3-methylimidazolium ionic liquid as a buffer additive by capillary electrophoresis. Journal of Pharmaceutical and Biomedical Analysis 41, 329-332 (2006).
  • Marszall M.P., Baczek T., Kaliszan R.: Evaluation of the silanol-supressing potency of ionic liquids. Journal of Separation Science 29, 1138-1145 (2006).
  • Wiczling P., Kawczak P., Nasal A., Kaliszan R.: Simultaneous determination of pKa and lipophilicity by gradient RP HPLC. Analytical Chemistry 78, 239-249 (2006).
  • Kaliszan W., Petrusewicz J., Kaliszan R.: Imidazoline receptors in relaxation of acetylcholine-constricted isolated rat jejunum. Pharmacological Reports 58, 700-710 (2006).
  • Frackowiak T., Baczek T., Kaliszan R., Zbikowska B., Glensk M., Fecka I., Cisowski W.: Binding of an oxindole alkaloid from Uncaria tomentosa to amyloid protein. Z. Naturforsch. 61c, 821-826 (2006).
2005
  • Bucinski A., Baczek T., Kaliszan R., Nasal A., Krysinski J., Zaluski J., Artificial neural network analysis of patient and treatment variables as a prognostic tool in breast cancer after mastectomy, Advances in Clinical and Experimental Medicine, 14, 973-979 (2005).
  • Marszall M.P., Baczek T., Kaliszan R., Reduction of silanophilic interactions in liquid chromatography with the use of ionic liquids, Analytica Chimica Acta, 547,172-178 (2005).
  • Baczek T., Marszall M.P., Kaliszan R., Walijewski L., Makowiecka W., Sparzak B., Grzonka Z.,
    Wisniewska K., Juszczyk P., Behavior of peptides and computer-assisted optimization of peptides separations
    in normal-phase thin-layer chromatography system with and without the addition of ionic liquid in the
    eluent, Biomedical Chromatography, 19 1-8 (2005).
  • Kaliszan R., Baczek T., Cimochowska A., Juszczyk P., Wisniewska K., Grzonka Z.: Prediction of HPLC retention of peptides with the use of quantitative structure-retention relationships, Proteomics, 5, 409-415 (2005)
  • Baczek T., Wiczling P., Marszall M.P., Vander Heyden Y., Kaliszan R., Prediction of peptides retention
    at different HPLC conditions from multiple linear regression models, Journal of
    Proteome Research, 4, 555-563 (2005).
  • Baczek T., Kaliszan R., Novotna K., Jandera P.: Comparative characteristics of HPLC columns based on quantitative structure-retention relationships (QSRR) and hydrophobic-subtraction model, Journal of Chromatography. A. 1075, 109-115 (2005).
  • Markuszewski M. J., Szczykowska M., Siluk D., Kaliszan R.: Human red blood cells targeted metabolome analysis of glycolysis cycle metabolites by capillary electrophoresis using an indirect photometric detection method, Journal of Pharmaceutical and Biomedical Analysis, 39, 636-642 (2005).
  • Wiczling P., Markuszewski M.J., Kaliszan M., Kaliszan R.: pH/Organic solvent double gradient reversed-phase HPLC, Analytical Chemistry, 77, 449-456 (2005).
  • Wiczling P., Markuszewski M.J., Kaliszan M., Geler K., Kaliszan R.: Combined pH/gradient solvent gradient HPLC in analysis of forensic.
    Journal of Pharmaceutical and Biomedical Analysis, 37, 871-875 (2005).
  • Kaliszan R., Wiczling P.: Theoretical opportunities and actual limitations of pH gradient HPLC, Analytical and Bioanalytical Chemistry, 382,718-727 (2005).
  • Kaliszan M., Hauser R., Kaliszan R., Wiczling P., Buczynski J., Penkowski M., Verification of the exponential model of body temperature decrease after death in pigs, Experimental Physiology, 90, 727-738, (2005).


2004

  • Kaliszan R., Wiczling P., Markuszewski M.J.: pH gradient reversed-phase HPLC.
    Analytical Chemistry, 76, 749-760 (2004).
  • Kaliszan R., Wiczling P., Markuszewski M.J.: pH gradient HPLC. Theory and application.
    Journal of Chromatography A, 1060,165-175 (2004).
  • Wiczling P., Markuszewski M.J., Kaliszan R.: Determination of pKa by pH gradient reversed-phase HPLC.
    Analytical Chemistry, 76, 3069-3077 (2004).
  • Krauze-Baranowska M., Baczek T., Glód D., Kaliszan R., Wollenweber R.: HPLC separation of O-acetylated flavonoids and biflavones from some species of Gymnospermae. Chromatographia, 60, 9-15 (2004).
  • Baczek T., Bucinski A., Ivanov A.R., Kaliszan R.: Artificial neural network analysis for evaluation of peptide MS/MS spectra in proteomics.
    Analytical Chemistry, 76, 1726-1732 (2004).
  • Kaliszan R., Marszall M.P., Markuszewski M.J., Baczek T., Pernak J.: Suppression of deleterious effects of free silanols in liquid chromatography by imidazolium tetrafluoroborate ionic liquids.
    Journal of Chromatography A, 1030, 263-271 (2004).
  • Kaliszan R., Markuszewski M.J., Wiczling P.: Combined pH/Organic modifier double gradient reversed-phase HPLC.
    Polish Journal of Chemistry, 78, 1047-1056 (2004).
  • Bucinski A., Markuszewski M.J., Wiktorowicz W., Krysinski J., Kaliszan R.: Artificial neural networks for prediction of antibacterial activity in series of imidazole derivatives.
    Combinatorial Chemistry & High Throughput Screening, 7, 327-336 (2004).


2003

  • Buszewski B., Krupczynska K., Gadzala-Kopciuch R.M., Rychlicki G., Kaliszan R.: Evaluation of HPLC columns: A study on surface homogeneity of chemically bonded stationary phases.
    Journal of Separation Science, 26, 313-321 (2003).
  • Vonk E.C., Lewandowska K., Claessens H.A., Kaliszan R., Cramers C.A.: Quantitative structure-retention relationships in reversed-phase liquid chromatography using several stationary and mobile phases.
    Journal of Separation Science, 26, 777-792 (2003).
  • Kaliszan R., Baczek T., Bucinski A., Buszewski B., Sztupecka M.: Prediction of gradient retention from the linear solvent strenght (LSS) model, quantitative structure-retention relationships (QSRR), and artificial neural networks (ANN).
    Journal of Separation Science, 26, 271-282 (2003).
  • Markuszewski M.J., Kaliszan R.: Chromatografia w metabolice, Kompleksowa ocena jakosci substancji leczniczych i postaci leków. Materialy Konferencji Naukowej, Poznan, 18-19 wrzesnia, 15 poz. bibliogr., 22-25 (2003).
  • Kaliszan R., Nasal A., Markuszewski M.J.: New approaches to chromatographic determination of lipophilicity of xenobiotics, Analytical and Bioanalytical Chemistry 377, 803-811 (2003).
  • Kaliszan R., Markuszewski M.J.: Studies on correlation between structure of solutes and their retention.
    Chemia Analityczna (Warsaw), 48, 373 (2003).
  • Nasal A., Siluk D., Kaliszan R.: Chromatographic retention parameters in medicinal chemistry and molecular pharmacology.
    Current Medicinal Chemistry, 10, 381-426 (2003).
  • Baczek T., Kaliszan R.: Predictive approaches to gradient retention based on analyte structural descriptors from calculation chemistry.
    Journal of Chromatography A 987, 29-37 (2003).


2002

  • Baczek T., Kaliszan R.: Combination of linear solvent strength model and quantitative structure-retention relationships as a comprehensive procedure of approximate prediction of retention in gradient liquid chromatography.
    Journal of Chromatography A 962, 41-55 (2002).
  • Wiktorowicz W., Markuszewski M., Krysinski J., Kaliszan R.: Quantitative structure-activity relationships study of a series of imidazole derivatives as potential new antifungal drugs.
    Acta Poloniae Pharmaceutica-Drug Research Vol. 50, 295-305 (2002).
  • Bucinski A., Krysinska I., Sowinski J., Baczek T., Kaliszan R.: Principal component analysis of patient variables as an objective method of classification of thyroid disorders.
    Polish Journal of Endocrinology, 53, 123-136 (2002).
  • Jiskra J., Claessens H.A., Cramers C.A., Kaliszan R.: Quantitative structure-retention relationships in comparative studies of behavior of stationary phases under high-performance liquid chromatography and capillary electrochromatography conditions.
    Journal of Chromatography A 977, 193-206 (2002).
  • Siluk D., Kaliszan R., Haber P., Petrusewicz J., Brzozowski Z., Sut G.: Antiaggregatory activity of hypoglycaemic sulphonylureas.
    Diabetologia 45, 1034-1037 (2002).
  • Calleri E., De Lorenzi E., Siluk D., Markuszewski M., Kaliszan R., Massolini G.: Riboflavin binding protein chiral stationary phase: Investigation of retention mechanism.
    Chromatographia 55, 651-658 (2002).
  • Kaliszan R., Haber P., Baczek T., Siluk D., Valko K.: Lipophilicity and pKa estimates from gradient high-performance liquid chromatography.
    Journal of Chromatography A 965, 117-127 (2002).
  • Wiktorowicz W., Krysinski J., Skrzypczak A., Kaliszan R.: Quantitative relationships between structure and anti-electrostatical properties of quaternary ammonium salts.
    S.T.P. Pharma Sciences 12 (3), 181-190 (2002).
  • Nasal A., Wojdelko A., Baczek T., Kaliszan R., Cybulski M., Chilmonczyk: Relationship between chromatographic behavior and affinity to HT1A serotonin receptors of new buspirone analogues.
    Journal of Separation Sciences 25, 273-279 (2002).
  • Bucinski A., Kowalski I.M., Zarzycki D., Baczek T., Nasal A., Kaliszan R.: Principal component analysis of patient variables as an objective method of treatment evaluation in adolescent idiopathic scoliosis.
    Advances in Clinical and Experimental Medicine 11, 61-68 (2002).
  • Kaliszan R., Rynkiewicz A., Deptulski T., Siluk D., Haber P., Markuszewski M., Baczek T., Dabrowska A., Nasal A., Damasiewicz B., Radwanska A., Frackowiak T.: Ocena dostepnosci biologicznej furosemidu z preparatu Furosemidum tabl. 40 mg w porównaniu z odpowiednikiem leku badanego.
    Terapia i Leki, LII/2, 37-39 (2002).


2001

  • Baczek T., Kaliszan R.: Quantitative structure/retention relationships in affinity chromatography.
    Journal Biochem. Biophys Methods 49, 83-98 (2001).
  • Kaliszan R., Haber P., Baczek T., Siluk D.: Gradient HPLC in the determination of drug lipophilicity and acidity.
    Pure and Applied Chemistry 73,1465-1475 (2001).
  • Chilmonczyk Z., Siluk D., Kaliszan R., Lozowicka B., Poplawski J., Filipek S.: New chemical structures of hypolipidemic and antiplatelet acivity.
    Pure and Applied Chemistry 73,1445-1458 (2001).
  • Forgács, Cserháti T., Balough S., Kaliszan R., Haber P., Nasal A.: Separation of strength and selectivity of mobile phase by spectral mapping technique.
    Biomedical Chromatography 15, 348-355 (2001).
  • Buszewski B., Jezierska-Switala M., Kaliszan R., Wojtczak A., Albert K., Bachmann S., Matyska M.T., Pesek J.J.: Selectivity tuning and molecular modeling of new generation packings for RP HPLC.
    Chromatographia 53(suppl.),S204-S212(2001).
  • Frackowiak T., Markuszewski M., Kaliszan R.: Estimation of buspirone-bovine serum albumin binding by affinity capillary electrophoresis.Acta Poloniae Pharmaceutica – Drug Research 58, S319-323, (2001).
  • Falandysz J., Puzyn T., Szymanowska B., Kawano M., Markuszewski M., Kaliszan R., Skurski P., Blazejowski J., Wakimoto T.: Thermodynamic and physico-chemical descriptors of chloronaphthalenes: an attempt to select features explaining environmental behaviour and specific toxic effects of these compounds.Polish Journal of Environmental Studies 10, 217-235 (2001).
  • Baczek T., Kaliszan R., Claessens H., van Straten M.A.: Computer-Assisted optimization of reversed-phase HPLC isocratic separations of neutral compounds.
    LC/GC, 14, 304-313 (2001).
  • Baczek T., Lewandowska G., Kaliszan R., Krauze-Baranowska M., Cisowski W.: Computer assisted optimization of gradient HPLC method of separations of flawonoids from Taxus baccata var. Elegantissima and metasequoia glyptostroboides.LC/GC Europe website, 1 (suppl.), 25-33 (2001).
  • Mehdi A.Al-Haj, Kaliszan R., Buszewski B.: Quantitative structure-retention relationships (QSRR) with model analytes as means of objective evaluation of chromatographic columns.Journal of Chromatographic Science, 39, 29-38 (2001).


2000

  • Bucinski A., Zaluski J., Krysinski J., Kaliszan R.: Principal component analysis of patients, disease and treatment variables: a new prognostic tool in breast cancer after mastectomy.
    Reports in Practical Oncology and Radiotherapy, 5, 83-89 (2000).
  • Bucinski A., Nasal A., Kaliszan R.: Pharmacological classification of drugs based on neural network processing of molecular modeling data.Combinatorial Chemistry and High Throughput Screening, 3, 525-533 (2000).
  • Baczek T., Markuszewski M., Kaliszan R., van Straten M.A., Claessens H.: Linear and quadratic relationships between retention and organic modifier content in eluent in reversed phase high-performance liquid chromatography: a systematic comparative statistical study.
    Journal Journal of High Resolution Chromatography 23, 667-676 (2000).
  • Haber P., Baczek T., Kaliszan R., Snyder L.R., Dolan J.W., Wehr C.T.: Computer simulation for the simultaneous optimization of any two variables and any chromatographic procedure.Journal of Chromatographic Science, 38, 386-392 (2000).
  • Poplawski J., Lozowicka B., Dubis A.T., Lachowska B., Witkowski S., Siluk D., Perusewicz J., Kaliszan R., Strzalkowska M. and Chilmonczyk Z.: Synthesis and hypolipidemic and antiplatelet activities of -asaroneisomers in humans (in vitro), mice (in vivo), and rats in vivo).Journal of Medicinal Chemistry, 43, 3771-3676 (2000).
  • Kepczynska E., Bojarski J., Haber P., Kaliszan R.: Retention of barbituric acid derivatives on immobilized artificial membrane stationary phase and its correlation with biological activity.
    Biomedical Chromatography, 14, 256-260 (2000).
  • Jezierska M., Cendrowska J., Markuszewski M., Kaliszan R., Buszewski B.: Comparative study of surface topography of high performance liquid chromatography columns in terms of hydrophobicity.
    Chromatographia, 51, 111-118 (2000).


1999

  • Petrusewicz J., Siluk D., Kaliszan R., Foks H., Nowakowska E.: Comparative study of antithrombotic and antiaggregatory activity of acetylsalicylic acid, ticlopidine and new noncarboxylic acid antiinflammatory pyrazine derivative HF90.
    Acta Poloniae Pharmaceutica – Drug Research, 56, 463-467 (1999).
  • Cserháti T., Forgács E., Kósa A., Csiktusnádi Kiss G., Kaliszan R., Haber P., Nasal A., Örsi F.: Binding of environmental pollutants to the wheat protein gliadin studied by high-performance liquid chromatography.
    Journal of Chromatographic Science, 37, 159-164 (1999).
  • Al.-Haj M.A., Kaliszan R., Nasal A.: Test analytes for studies of the molecular mechanism of chromatographic separations by quantitative.
    Analytical Chemistry 71, 2976-2985 (1999).
  • Kaliszan R., van Straten M.A., Markuszewski M., Cramers C.A., Claessens H.A.: Molecular mechanism of retention in reversed-phase high-performance liquid chromatography and classification of modern stationary phases by using quantitative structure-retention relationships
    Journal of Chromatography A, 855, 455-486 (1999).
  • Buszewski B., Jezierska M., Welniak M., Kaliszan R.: Cholesteryl-silica stationary phase for liquid chromatography Comparative study of retention behavior and selectivity.
    Journal of Chromatography A, 845, 433-445 (1999).
  • Dolan J.W., Snyder L.R., Wolcott R.G., Haber P., Baczek T.,
    Kaliszan R., Sander L.C.: Reversed-phase liquid
    chromatographic separation of complex samples by optimizing
    temperature and gradient time III. Improving the accuracy of
    computer simulation.
    Journal of Chromatography A, 857, 41-68 (1999).


1998

  • Wozniak A., Limon J., Petrusewicz J., Kaliszan R.: Effects of acetylsalicylic acid and a new pyrazine derivative PD-101 on sister chromatid exchange frequency and cell kinetics in cultured human lymphocytes.
    Journal of Applied Genetics, 30, 281-287 (1998).
  • Petrusewicz J., Markuszewski M., Haber P., Nasal A.,
    Damasiewicz B., Radwanska A., Kaliszan R., Deptulski T., Rynkiewicz A.: Badanie biodostepnosci i biorównowaznosci bisoprololu z preparatów Bisocard i OLB.
    Terapia i Leki, XXIV/XLVIII, 247-254 (1998).
  • Forgacs E., Cserhati T., R., Kaliszan R, Haber P., Nasal A.: Reversed-phase thin-layer chromatograpic determination of
    the hydrophobicity parameters of nonsteroidal anti-
    inflammatory drugs.
    Journal of Planar Chromatography, 11, 383-387 (1998).
  • Al-Haj M.A., Haber P., Kaliszan R., Buszewski B., Jezierska M., Chilmonczyk Z.: Mechanism of separation on cholesterol- silica stationary phase for high-performance liquid chromatography as revealed by analysis of quantitative structure-retention relationships.
    Journal of Pharmaceutical and Biomedical Analysis, 18, 721-
    728 (1998).
  • Kaliszan R., Markuszewski M., Haber P., Nasal A., Buszewski B., Gadzala-Kopciuch R.M., Cesrhati T., Forgacs E.: Quantitative structure-retention relationships (QSRR) in evaluation of new stationary phases for high-performance liquid chromatography (HPLC).
    Chem. Anal. (Warsaw), 43, 547-559 (1998).
  • Forgacs E., Kosa A., Csiktusnadi Kiss G., Kaliszan R., Haber P., Nasal A.: Use of modified nonlinear mapping method in quantitative structure-retention relationship study.
    Journal of Liquid Chromatography & Related Technologies, 21, 2523-2534 (1998).
  • Buszewski B., Kaliszan R., Gadzala-Kopciuch R., Markuszewski M., Matyska M.T., Pesek J.J.: Polyfunctional chemically bonded stationary phase for reversed phase high performance liquid chromatography.
    Chromatographia, 48, 615-622 (1998).
  • Markuszewski M., Krass J.D., Hippe T., Jastorff B., Kaliszan R.: Separation of nitroaromatics and their transformation products in soil around ammunition plants: new high- performance liquid chromatographic charge transfer stationary phases.
    Chemosphere, 37, 559-575 (1998).
  • Nasal A., Payer K., Haber P., Forgacs E., Cserhati T., Kaliszan R.: Quantitative structure-retention relationships in studies of mechanism of separation on polyethylene-coated silica and alumina stationary phases.
    LC.GC International, 11, 240-252 (1998).
  • Bober L., Nasal A., Kuchta A., Kaliszan R.: Chemometric analysis of high-performance liquid chromatography retention data, structural parameters and biological activity of sulphonamides.
    Acta Chromatographica, 8, 48-69 (1998).
  • Turowski M., Kaliszan R.: Collagen immobilised on silica derivatives as a new stationary phase for HPLC.
    Biomedical Chromatography, 12, 187-192 (1998).


1997

  • Kaliszan R., Turowski M.: Chromatographic systems which model interactions of drugs with keratin and collagen.
    Herba Polonica, 43, 339-345 (1997).
  • Nasal A., Bucinski A., Bober L., Kaliszan R.: Prediction of pharmacological classification by means of chromatographic parameters processsed by principal component analysis.
    International Journal of Pharmaceutics, 159, 43-45 (1997).
  • Chilmonczyk Z., Ksycinska H., Mazgajska M., Cybulski J., Kaliszan R.: Nonlinear structure-enantioselective retention relationships in a homologous series of 1,4-disubstituted piperazine derivatives.
    Journal of Chromatography A, 788, 81-85 (1997).
  • Buszewski B., Gadzala-Kopciuch R.M., Markuszewski M., Kaliszan R.: New chemically bonded silica stationary phases: synthesis, physicochemical characterization and molecular mechanism of reversed-phase HPLC retention.
    Analytical Chemistry, 69, 3277-3284 (1997).
  • Abraham M.H., Chadha H.S., Leitao R.A.E., Mitchell R.C., Lambert W.J., Kaliszan R., Nasal A., Haber P.: Determination of solute lipophilicity, as log P (octanol) and log P (alkane) using poly(styrene-divinylbenzene) and immobilised artificial membrane stationary phases in reversed phase reversed-phase high-performance liquid chromatography.
    Journal of Chromatography A, 706, 35-47 (1997).
  • Turowski M. Kaliszan R.: Keratin immobilized on silica as a new stationary phase for chromatographic modelling of skin permeation.
    Journal of Pharmaceutical and Biomedical Analysis, 15, 1325- 1333 (1997).


1996-1995

  • Szefer P., Szefer K., Glasby G.P., Pempkowiak J., Kaliszan R.: Heavy-metal pollution in surficial sediments from the southern Baltic Sea off Poland.
    Journal of Environmental Science and Health, A31, 2723-2754 1996).
  • Nasal A., Haber P., Kaliszan R., Forgacs E., Cserhati T., Abraham M.H.: Polyethylene-coated silica and zirconia stationary pahses in view of quantitative structure- retention relationships.
    Chromatographia, 43, 484-490 (1996).
  • Kaliszan R., Markuszewski M.: Brain/blood distribution described by a combination of partition coefficient and molecular mass.
    International Journal of Pharmaceutics, 145, 9-16 (1996).
  • Petrusewicz J., Nasal A., Radwanska A., Frackowiak T., Turowski M., Markuszewski M., Deptulski T., Rynkiewicz A., Kaliszan R.: Badania nad farmakokinetyka i farmakodynamika metoprololu.
    Problemy Terapii Monitorowanej, 7, 136-140 (1996).
  • Turowski M., Kaliszan R., Lüllmann, Genieser H.G., Jastorff B.: New HPLC stationary phases for separation of nucleosides and cyclic nucleotides: Synthesis and chemometric analysis of retention data.
    Journal of Chromatography A, 728, 201-211 (1996).
  • Kaliszan R., Nasal A., Turowski M.: Quantitative structure- retention relationships in examination of topography of binding site of antihistamine drugs on a1-acid glycoprotein.
    Journal of Chromatography A, 722, 25-32 (1996).
  • Stozkowska W., Gami Yilinkou R., Kaliszan R.: Urinary silver and sulafathiazole levels in thermally injured guinea pigs during treatment with silver sulfathiazole cream.
    Scientific and Technical Pharmacy – Pharmaceutical Sciences, 5, 452-455 (1995).
  • Radwanska A., Frackowiak T., Ibrahim H., Aubry A.-F., Kaliszan R.: Chromatographic modelling of interactions between melanin and phenothiazine and dibenzazepine drugs.
    Biomedical Chromatography, 9, 233-237 (1995).
  • Kaliszan R., Nasal A., Turowski M.: Binding site for basic drugs on a1-acid glycoprotein as revealed by chemometric analysis of biochromatographic data.
    Biomedical Chromatography, 9, 211-215 (1995).
  • Pelplinska T., Regosz A., Kaliszan R.: Quantitative structure-solubility relationships for hydantoin and barbituric acid derivatives.
    Acta Pharmaceutica, 45, 97-108 (1995).
  • Kaliszan R., Turowski M., Bucinski A., Hartwick R.A.: Quantitative structure-retention relationships in capillary electrophoresis of inorganic cations and b-adrenolytic and sulphonamides compounds.
    Quantitative Structure-Activity Relationships, 14, 356-361 (1995).
  • Nasal A., Frackowiak T., Petrusewicz J., Bucinski A., Kaliszan R.: Mydriasis elicited by imidazol(in)e a2- adrenomimetics in comparison with other adrenoceptor- mediated effects and hydrophobicity.
    European Journal of Pharmacology, 274, 125-132 (1995).
  • Szefer P., Glasby G.P., Pempkowiak J., Kaliszan R.: Extraction studies of haevy-metal pollutants in surficial sediments from the southern Baltic Sea off Poland.
    Chemical Geology, 120, 111-126 (1995).
  • Petrusewicz J., Turowski M., Foks H., Pilarski B., Kaliszan R.: Comparative studies of antiplatelet activity of non- steroidal antiinflammatory drugs and new pyrazine CH- and NH-acids.
    Life Sciences, 56, 667-677 (1995).
  • Nasal A., Sznitowska M., Bucinski A., Kaliszan R.: Hydrophobicity parameter from high-performance liquid chromatography on an immobilized artificial membrane column and its relationship to bioactivity.
    Journal of Chromatography A, 692, 83-89 (1995).


1994-1993

  • Nasal A., Radwanska A., Osmialowski K., Bucinski A., Kaliszan R., Barker G.E., Sun P., Hartwick R.A.: Quantitative relationships between structure of b- adrenolytic and antihistamine drugs and their retention on an a1-acid glycoprotein HPLC column.
    Biomedical Chromatography, 8, 125-129 (1994).
  • Kaliszan R., Nasal A., Bucinski A.: Chromatographic hydrophobicity parameter determined on an immobilized artificial membrane column: relationships to standard measures of hydrophobicity and bioactivity.
    European Journal of Medicinal Chemistry, 29, 163-170 (1994).
  • Sun P., Barker G.E., Hartwick R.A., Grinberg N., Kaliszan R.: Chiral separations using an immobilized protein-dextran polymer network in affinity capillary electrophoresis.
    Journal of Chromatography A, 652, 247-252 (1993).
  • Szefer P., Kaliszan R.: Distribution of elements in sediment cores of the Southern Baltic from the point of view of principal component analysis.
    Studia i Materialy Oceanologiczne, 64, 95-102 (1993).
  • Szefer P., Pempkowiak J., Kaliszan R.: Distribution of elements in surficial sediments of the Southern Baltic determined by factor analysis.
    Studia i Materialy Oceanologiczne, 64, 85-93 (1993).
  • Radwanska A., Kaliszan R.: Comparative analysis of effects of imidazol(in)e drugs on isolated rat heart atria.
    Journal of Physiology and Pharmacology 44, 73-87 (1993).
  • Petrusewicz J., Gami-Yilinkou R., Kaliszan R., Pilarski B., Foks H.: Pyrazine CH- and NH-acids. Antithrombotic activity and chromatographic behaviour.
    General Pharmacology 24, 17-22 (1993).
  • Kaliszan R., Kaliszan A., Wainer I.W.: The prediction of drug binding to melanin using a melanin-based HPLC stationary phase and chemometric analysis of the chromatographic data.
    Journal of Chromatography Biomedical Applications, 615, 281- 288 (1993).
  • Kaliszan R., Kaliszan A., Wainer I.W.: Deactivated hydrocarbonaceous silica and immobilized artificial membrane stationary phases in high-performance liquid chromatographic determination of hydrophobicities of organic bases: Relationship to log P and CLOGP.
    Journal of Pharmaceutical and Biomedical Analysis, 11, 505- 511 (1993).
  • Gami-Yilinkou R., Nasal A., Kaliszan R.: Application of chemometrically processed chromatographic data for pharmacologically relevant classification of antihistamine drugs.
    Journal of Chromatography 633, 57-63 (1993).


1992-1991

  • Gami-Yilinkou R., Kaliszan R.: High performance liquid chromatographic (HPLC) measures of hydrophobicity as determined by means of new HPLC columns.
    Polish Journal of Pharmacology and Pharmacy 44, 515-525 (1992).
  • Foks H., Rudnicka W., Glówka M., Kaliszan R., Nasal A., Damasiewicz B., Radwanska A., Petrusewicz J., Trzeciak H., Okopien B., Janowiec M., Zwolska-Kwiek Z.: Synthesis, structure and biological activity of 1,2,4-triazolo-1,3- thiazine derivatives.
    Die Pharmazie 47, 770-773 (1992).
  • Kaliszan R., Kaliszan A., Noctor T.A.G., Purcell W.P., Wainer I.W.: Mechanism of retention of benzodiazepines in affinity, reversed phase and adsorption high performance liquid chromatography in view of quantitative structure retention relationships.
    Journal of Chromatography 609, 69-81 (1992).
  • Kaliszan R., Noctor T.A.G., Wainer I.W.: Stereochemical aspects of benzodiazepine binding to human serum albumin. II. Quantitative relationships between structure and enantioselective retention in high performance liquid affinity chromatography.
    Molecular Pharmacology 42, 512-517 (1992).
  • Noctor T.A.G., Pham C.D., Kaliszan R., Wainer I.W.: Stereochemical aspects of benzodiazepine binding to human serum albumin. I. Enantioselective high performance liquid affinity chromatographic examination of chiral and achiral binding interactions between 1,4 benzodiazepines and human serum albumin.
    Molecular Pharmacology 42, 506-511 (1992).
  • Kaliszan R., Noctor T.A.G., Wainer I.W.: Quantitative structure enantioselective retention relationships for the chromatography of 1,4 benzodiazepines on a human serum albumin based HPLC chiral stationary phase: an approach to the computational prediction of retention and enantio
    selectivity.
    Chromatographia 33, 546 550 (1992).
  • Petrusewicz J., Gami Yilinkou R., Pilarski B., Kaliszan R.: Antithrombotic activity of a new pyrazine derivative determined by the mouse antithrombotic assay.
    Pharmacology & Toxicology 70, 448 452 (1992).
  • Petrusewicz J., Damasiewicz B., Kaliszan R., Juzwa W., Lammek B., Derdowska I.: New antagonists of the vasopressin receptor mediated contraction in rat tail artery.
    Pharmacological Research 25, 167 172 (1992).
  • Bukowski L., Kaliszan R.: Imidazo[4,5 b]pyridine derivatives of potential tuberculostatic activity, II: Synthesis and bioactivity of designed and some other 2 cyanomethylimidazo [4,5 b]pyridine derivatives.
    Archiv der Pharmazie 324, 537 542 (1991).
  • Petrusewicz J., Kaliszan R.: Human blood platelet alpha adrenoceptor in view of the effects of various imidazol(in)e drugs on aggregation.
    General Pharmacology 15, 819 823 (1991).
  • Czarnocka Janowicz A., Foks H., Nasal A., Petrusewicz J., Damasiewicz B., Radwanska A., Kaliszan R.: Synthesis and pharmacological activity of 5 substituted-s triazole 3 thiols.
    Die Pharmazie 46, 109 112 (1991).
  • Regosz A., Osmialowski K., Kaliszan R.: Relationships between solubility of sulphonamides and their structural parameters.
    Acta Pharmaceutica Jugoslavica 41, 7 15 (1991).
  • Osmialowski K., Kaliszan R.: Studies of performance of graph theoretical indices in QSAR analysis.
    Quantitative Structure Activity Relationships 10, 134 140 (1991).
  • Gami Yilinkou R., Kaliszan R.: Chromatographic data for pharmacological classification of imidazol(in)e drugs.
    Journal of Chromatography 550, 573 584 (1991).
  • Bukowski L., Kaliszan R.: Imidazo[4,5 b]pyridine derivatives of potential tuberculostatic activity.
    Archiv der Pharmazie 324, 121 127 (1991).


1990-1986

  • Gami Yilinkou R., Kaliszan R.: Determination of hydrophobicity of organic bases on poly(butadiene) coated alumina and on octadecylsilica columns.
    Chromatographia 30, 277 (1990).
  • Kaliszan R., Osmialowski K.: Correlation between chemical structure of noncongeneric solutes and their retention on polybutadiene coated alumina.
    Journal of Chromatography 506, 3 (1990).
  • Kaliszan R., Osmialowski K., Bassler B., Hartwick R.A.: Mechanism of retention in high performance liquid chromatography on porous graphitic carbon as revealed by principal component analysis of structural descriptors of solutes.
    Journal of Chromatography 499, 333 (1990).
  • Nasal A., Kaliszan R., Foks H., Wisterowicz K.: Quantitative relationships between hydrophobicity and hypotensive activity of diazacycloalkane derivatives.
    Polish Journal of Pharmacology and Pharmacy 41, 649 (1989).
  • Bassler B.J., Kaliszan R., Hartwick R.A.: Retention mechanism on metallic stationary phases.
    Journal of Chromatography 461, 139 (1989).
  • Kaliszan R., Petrusewicz J., Blain R.W., Hartwick R.A.: Determination of hydrophobicity parameters on polybutadiene coated alumina and their application in quantitative structure activity relationships analysis.
    Journal of Chromatography 458, 395 (1988).
  • Regosz A., Wojtkiewicz T., Chmielewska A., Osmialowski K., Kaliszan R.: Dependence of solubility of tetracycline antibiotics on structural parameters of solvents.
    Acta Pharmaceutica Jugoslavica 38, 223 (1988).
  • Kaliszan R., Petrusewicz J., Juzwa W., Rekowski P., Lammek B., Kupryszewski G.: Constrictory activity of three new arginine vasopressin (AVP) analogues (ALA AVP, SER ALA AVP, THR SER ALA AVP) towards isolated rat tail artery as related to AVP alone.
    Pharmacological Research Communications 20, 377 (1988).
  • Juzwa W., Wierzba T., Redlarski G., Przyborska A., Kaliszan R.: Oksytocyna jako antagonista naczyniozwezajacego dzialania noradrenaliny w naczyniach trzewnych szczura.
    Annales Academiae Medicae Gedanensis 18, 105 (1988).
  • Petrusewicz J., Kaliszan R.: Antiaggregatory activity of imidazoline drugs and chemicals as a function of their structure.
    Agents and Actions 24, 204 (1988).
  • Kaliszan R., Blain R.W., Hartwick R.A.: A new HPLC method of hydrophobicity evaluation employing poly(butadiene) coated alumina columns.
    Chromatographia 25, 5 (1988).
  • Kaliszan R., Foks H., Damasiewicz B., Nasal A., Petrusewicz J., Radwanska A., Saczewski F., Kuzmierkiewicz W.: A search for new antihypertensive agents. II. Circulatory activity and selection of structures among 2 methylbenzimidazole derivatives.
    Polish Journal of Pharmacology and Pharmacy 39, 419 (1987).
  • Nasal A., Kaliszan R., Kuzmierkiewicz W.: Effect of substituents at position 2 on the 1H NMR chemical shift of protons of 2 methylbenzimidazole derivatives.
    Quantitative Structure Activity Relationships 6, 22 (1987).
  • Kaliszan R., Osmialowski K., Tomellini S.A., Hsu S. H., Fazio S.D., Hartwick R.A.: Quantitative retention relationships as a function of mobile and C18 stationary phase composition for non cogeneric solutes.
    Journal of Chromatography 352, 141 (1986).
  • Petrusewicz J., Kaliszan R.: Blood platelet adrenoceptor: Aggregatory and antiaggregatory activity of imidazoline drugs.
    Pharmacology 33, 249 (1986).
  • Lamparczyk H., Kaliszan R., Radecki A.: Correlation between retention on liquid crystalline phases and chemical structure.
    Journal of Chromatography 361, 442 (1986).
  • Kuzmierkiewicz W., Saczewski F., Foks H., Kaliszan R., Damasiewicz B., Nasal A., Radwanska A.: Syntheses and biological activities of 2 (adamantylmethyl)-benzimidazoles and imidazolines.
    Archiv der Pharmazie 319, 830 (1986).
  • Osmialowski K., Halkiewicz J., Kaliszan R.: Quantum chemical parameters in correlation analysis of gas liquid chromatographic retention indices of amines. II. Topological electronic index.
    Journal of Chromatography 361, 63 (1986).
  • Kaliszan R.: Surface electric charge of the active and inactive polymorphs of chloramphenicol palmitate.
    Journal of Pharmaceutical Sciences 75, 187 (1986).


1985-1981

  • Knox J.H., Kaliszan R.: Theory of solvent disturbance peaks and experimental determination of thermodynamic dead volume in column liquid chromatography.
    Journal of Chromatography 349, 211 (1985).
  • Kaliszan R., Osmialowski K., Tomellini S.A., Hsu S. H., Fazio S.D., Hartwick R.A.: Non empirical descriptors of submolecular polarity and dispersive interactions in reversed phase HPLC.
    Chromatographia 20, 705 (1985).
  • Petrusewicz J., Kaliszan R.: Effect of imidazoline drugs on human blood platelet aggregation.
    Thrombosis and Haemostasis 54, 784 (1985).
  • Kaliszan R., Damasiewicz B., Nasal A., Radwanska A., Foks H., Kuzmierkiewicz W., Pancechowska Ksepko D., Rudnicka W., Wisterowicz K., Osmialowski K.: Structure and alpha adrenergic activity of pyrazinimidazolines.
    Agents and Actions 16, 5 (1985).
  • 41. Pilarski B., Osmialowski K., Kaliszan R.: The relationship between electron densities and the electronic substituent constants for substituted pyridines.
    International Journal of Quantum Chemistry 28, 233 (1985).
  • Kaliszan R., Pilarski B., Osmialowski K., Strzalkowska Grad H., Hac E.: Analgesic activity of new pyrazine CH and NH acids and their hydrophobic and electron donating properties.
    Farmazeutisch Weekblad Scientific Edition 7, 141 (1985).
  • Kaliszan R., Foks H., Damasiewicz B., Nasal A., Radwanska A., Kuzmierkiewicz W., Pancechowska Ksepko D., Rudnicka W., Wisterowicz K.: A search for new antihypertensive agents. I. Alpha adrenergic activity and selection of structures among pyrazine substituted imidazolines.
    Polish Journal of Pharmacology and Pharmacy 37, 79 (1985).
  • Osmialowski K., Halkiewicz J., Radecki A., Kaliszan R.: Quantum chemical parameters in correlation analysis of gas liquid chromatographic retention indices of amines.
    Journal of Chromatography 346, 53 (1985).
  • Pilarski B., Foks H., Osmialowski K., Kaliszan R.: Studies on pyrazinyl-pyrazilidene tautomerism of pyrazine acetonitrile derivatives.
    Monatshefte für Chemie 115, 179 (1984).
  • Kaliszan R.: Suspended particles electric charge and crystal forms bioavailability.
    Zentralblatt fur Pharmazie 122, 696 (1983).
  • Kaliszan R., Holtje H. D.: Gas chromatographic determination of molecular polarity and quantum chemical calculations of dipole moments in a group of substituted phenols.
    Journal of Chromatography 234, 303 (1982).
  • Kaliszan R., Pankowski M., Szymula L., Lamparczyk H., Nasal A., Tomaszewska B., Grzybowski J.: Structure olfactory activity relationship in a group of substituted phenols.
    Die Pharmazie 37, 499 (1982).
  • Lamparczyk H., Radecki A., Kaliszan R.: Application of a geometric parameter defining molecular shape for the quantitation of interaction of polycyclic aromatic hydrocarbons with enzyme systems.
    Biochemical Pharmacology 30, 2337 (1981).


1980-1976

  • Knox J.H., Kaliszan R., Kennedy G.J.: Enthalpic exclusion chromatography.
    Journal of the Chemical Society, Faraday Symposiums 15, 113 (1980).
  • Jankowski T., Kaliszan R., Lamparczyk H.: Program komputerowy do badan ilosciowych zaleznosci struktura aktywnosc biologiczna metoda Hanscha.
    Acta Poloniae Pharmaceutica 37, 573 (1980).
  • Kaliszan R., Lamparczyk H., Radecki A.: A relationship between repression of dimethylnitrosamine demethylase by polycyclic aromatic hydrocarbons and their shape.
    Biochemical Pharmacology 28, 123 (1979).
  • Radecki A., Lamparczyk H., Kaliszan R.: A relationship between the retention indices on nematic and isotropic phases and the shape of polycyclic aromatic hydrocarbons.
    Chromatographia 12, 595 (1979).
  • Kaliszan R., Osmialowski K., Kobylczyk K.: In vitro activity of sulphonamides as a function of their molar refractivity.
    Chemotherapy 25, 5 (1979).
  • Kaliszan R., Kozakiewicz I., Gajewski F., Madrala A.: QSAR studies in a series of new hypoglycemic sulphonamides.
    Die Pharmazie 34, 246 (1979).
  • Kaliszan R.: The relationship between the connectivity indices and the thermodynamic parameters describing the interaction of fatty acid methyl esters with polar and nonpolar stationary phases.
    Chromatographia 12, 171 (1979).
  • Kaliszan R., Lamparczyk H.: The relationship between the retention indices and the connectivity indices of polycyclic aromatic hydrocarbons.
    Journal of Chromatographic Science 16, 246 (1978).
  • Kaliszan R., Milczarska B., Lega B., Szefer P., Janowiec M: Studies on quantitative relationships between the structure and in vitro tuberculostatic potency of 2 cyanomethylbenz- imidazole derivatives.
    Polish Journal of Pharmacology and Pharmacy 30, 585 (1978).
  • Kaliszan R., Foks H., Janowiec M.: Studies on the quantitative structure activity relationships in pyrazine carbothioamide derivatives.
    Polish Journal of Pharmacology and Pharmacy 30, 579 (1978).
  • Kaliszan R.: Correlation between gas chromatographic retention indices and the connectivity indices of cyclic alcohols and methyl esters.
    Chromatographia 10, 529 (1977).
  • Kaliszan R., Foks H.: The relationship between the RM values and the connectivity indices for pyrazine carbothioamide derivatives.
    Chromatographia 10, 346 (1977).
  • Kaliszan R., Hac E.: Calcium bromide clathrates of barbital and carbromal. Studies on bioavailability by various pharmacological tests.
    Scientia Pharmaceutica 45, 1 (1977).
  • Kaliszan R., Bober L.: Allantoin ethylenediamine solid systems.
    Zentralblatt fur Pharmazie 115, 719 (1976).
  • Kaliszan R.: Studies on the polymorphism of 5 allyl 5 (2’ hydroxy propyl) barbituric acid.
    Die Pharmazeutische Industrie 38, 1016 (1976).
  • Kaliszan R.: Analytical studies on crystals of theophylline obtained at various conditions.
    Pharmacutica Acta Helvetiae 51, 159 (1976).
  • Grabowska I., Kaliszan R.: Studies on the polymorphism of barbital.
    Polish Journal of Pharmacology and Pharmacy 28, 529 (1976).
  • Kaliszan R., Hac E.: Studies on the polymorphism of carbromal.
    Die Pharmazie 31, 453 (1976).


1975-1970

  • Kaliszan R., ‘Onadeko B.: Analysis of crystalline samples of allantoin, chlorethylaminouracil and mephenytoin which were obtained at various conditions.
    Scientia Pharmaceutica 43, 243 (1975).
  • Kaliszan R., Halkiewicz J.: IR analysis of crystalline samples of some urea derivatives.
    Polish Journal of Pharmacology and Pharmacy 27, 579 (1975).
  • Kaliszan R.: Electrets and drug’s bioavailability theoretical considerations.
    Die Pharmazeutische Industrie 37, 187 (1975).
  • Grabowska I., Kaliszan R.: Modyfikacje krystaliczne 5,5 dwufenylo hydantoiny.
    Acta Poloniae Pharmaceutica 31, 721 (1974).
  • Grabowska I., Kaliszan R.: Dimorphism of ureides: Bromiso- valerylurea (Bromisoval) and bromdiethylacetylcarbamide (Carbromal).
    Polish Journal of Pharmacology and Pharmacy 26, 527 (1974).
  • Grabowska I., Kaliszan R., Zoga P.: Polimorfizm kwasu 5 allilo 5 (2’ hydroksypropylo) barbiturowego.
    Acta Poloniae Pharmaceutica 31, 189 (1974).
  • Kaliszan R., Janicki H.: Dimorphism of pyrimidine bases.
    Acta Poloniae Pharmaceutica 31, 121 (1974).
  • Grabowska I., Kaliszan R., Kucinski W.: A method of evaluation of quality of 4 methyl 5 [bis (2’ chloroethyl) amino] uracil.
    Polish Journal of Pharmacology and Pharmacy 25, 621 (1973).
  • Grabowska I., Kaliszan R.: Dimorphism of 3 methyl 5 ethyl 5 phenyl imidazolidinedione 2,4.
    Arzneimittel Forschung 23, 1477 (1973).
  • Grabowska I., Kaliszan R.: Polimorfizm 4 metylo 5 [bis (2’ chloro etylo) amino] uracylu (Dopan ZSRR).
    Farmacja Polska 29, 329 (1973)
  • Grabowska I., Kaliszan R., Zoga P.: Badanie trwalosci roztworów kwasu 5 allilo 5 (2’ hydroksypropylo) barbiturowego.
    Acta Poloniae Pharmaceutica 30, 173 (1973).
  • Grabowska I., Kaliszan R., Zoga P.: Oznaczanie kwasu 5 allilo 5 (2’ hydroksypropylo) barbiturowego w roztworach rozlozonych.
    Acta Poloniae Pharmaceutica 29, 591 (1972).
  • Grabowska I., Kaliszan R.: Bimorfizm pochodnych mocznika.
    Acta Poloniae Pharmaceutica 29, 537 (1972).
  • Regosz A., Kaliszan R.: Polarografia niektórych półsyntetycznych pochodnych tetracyklin.
    Farmacja Polska 26, 1039 (1970).
Aktualizacja strony: 25.09.2023
Joanna Dawidowska, Michał Markuszewski, Paweł Wiczling